<DOC>
	<DOCNO>NCT00460798</DOCNO>
	<brief_summary>This non-interventional study include patient advance and/or metastatic renal cell carcinoma treat SUTENT receive systemic therapy . The aim trial increase knowledge quality life , safety , efficacy tolerability condition routine use Sutent . The individual observation period patient 1 year .</brief_summary>
	<brief_title>SUTENTÂ® In The First Line Treatment Of Renal Cell Carcinoma</brief_title>
	<detailed_description>The Statistical Analysis Plan provide detailed specification analysis</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Firstline treatment patient metastatic renal cell carcinoma Any previous systemic therapy renal cell carcinoma except adjuvant treatment</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Sunitinib</keyword>
	<keyword>kidney disease</keyword>
	<keyword>urogenital neoplasm</keyword>
	<keyword>kidney cancer</keyword>
</DOC>